Business Context and Reporting Period
Company: Organogenesis Holdings Inc. (ORGO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Organogenesis is a regenerative medicine company focused on advanced wound care and surgical/sports medicine markets. Key products include Apligraf, Dermagraft (currently suspended), PuraPly, and placental-based allografts. The company operates as a single segment.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Product Revenue | $563.0 million | $482.0 million | +17% |
| Total Revenue | $564.2 million | $482.0 million | +17% |
| Gross Profit | $425.5 million | $366.3 million | +16% |
| Gross Margin | 75.4% | 76.0% | -0.6 pts |
| Net Income | $37.0 million | $0.9 million | Significant Increase |
| Adjusted EBITDA | $98.1 million | $49.8 million | +97% |
| Cash & Equivalents | $93.7 million | $135.6 million | -$41.9 million |
| Working Capital | $259.6 million | $208.5 million | +$51.1 million |
| Debt Obligations | $22.2 million (Finance Leases) | $1.9 million (Finance Leases) | Increased |
Note: The company had no outstanding borrowings under its Term Loan or Revolving Credit Facility as of December 31, 2025. The increase in finance lease obligations is primarily due to the commencement of the Smithfield Facility lease.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 17% to $563.0 million, driven primarily by the introduction of newly licensed products in the Advanced Wound Care segment and increased customer buying patterns in Surgical & Sports Medicine.
- Profitability: Net income surged to $37.0 million from $0.9 million in 2024. This improvement was aided by revenue growth and the absence of the $18.8 million property impairment and $4.0 million software write-down recorded in 2024.
- One-Time Charges: In 2025, the company recorded an $11.2 million write-down to fair value for an asset held for sale (a building in Canton, MA). This contrasts with 2024, which saw significant impairment charges related to property and construction.
- Capital Structure: In November 2024, the company issued Series A Convertible Preferred Stock (gross proceeds $130 million) and used proceeds to repay its Term Loan Facility and repurchase common stock. As of Dec 31, 2025, the liquidation preference of this preferred stock was approximately $142.2 million.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 11% to $326.2 million, largely due to higher commissions, credit loss allowances, and a one-time $4.7 million FDA fee for the ReNu Biologics License Application (BLA).
Guidance, Outlook, and Risks
Management Commentary & Outlook
- ReNu Pipeline: The company initiated a rolling Biologics License Application (BLA) for ReNu (knee osteoarthritis treatment) in late 2025, expecting completion in the first half of 2026. While a second Phase 3 trial did not achieve statistical significance for its primary endpoint, it showed numerical improvement and a favorable safety profile.
- Dermagraft Resumption: Manufacturing and sales of Dermagraft remain suspended. The company plans to transition manufacturing to a new facility in Smithfield, Rhode Island, with sales resumption targeted for the end of 2027.
- Reimbursement Environment: The company is experiencing a significant year-over-year revenue decline in Q1 2026 due to CMS reimbursement changes. New rules effective Jan 1, 2026, reclassify skin substitutes as "incident-to supplies" with a fixed payment rate (~$127.14/sq cm), replacing the previous ASP-based model. The company notes uncertainty regarding the long-term impact of these changes.
Key Risks & Contingencies
- Reimbursement Policy Changes: Significant risk exists regarding CMS Local Coverage Determinations (LCDs) and payment reforms. Recent withdrawals of draft LCDs and the implementation of the WISeR Model (prior authorization) create uncertainty for product utilization and revenue.
- Regulatory Classification: Risk that FDA may determine certain placental-based products (Affinity, Novachor, NuShield) do not qualify for Section 361 HCT/P regulation, potentially requiring costly PMA approvals.
- Supply Chain: Dependence on a limited group of suppliers for human tissue and raw materials; disruptions could materially impact sales.
- Convertible Preferred Stock: The Series A Convertible Preferred Stock carries an 8% dividend (paid in-kind), increasing the liquidation preference and diluting common shareholders upon conversion. It represents approximately 30% of outstanding Class A common stock on an as-converted basis.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual revenue impact of the January 2026 CMS payment rule changes in upcoming quarterly reports, specifically the shift from ASP-based to fixed-rate reimbursement.
- ReNu BLA Status: Monitor the FDA's review timeline and decision on the rolling BLA submission for ReNu, expected to be completed in H1 2026.
- Dermagraft Timeline: Track progress on the Smithfield, RI facility build-out and FDA approval to confirm the feasibility of resuming Dermagraft sales by end of 2027.
- Preferred Stock Conversion: Assess the potential dilution impact if the Series A Convertible Preferred Stock is converted, noting the current liquidation preference of ~$142.2 million.
- Asset Sale: Confirm the status and final sale price of the Canton, MA building classified as "held for sale," which was written down by $11.2 million in 2025.